Zealand Pharma licenses GLP-1/gastrin peptide platform to Elvinix for type 1 diabetes
Zealand Pharma has licensed its GLP-1/gastrin dual-agonist peptide platform to Elvinix for development as a potentially regenerative treatment for type 1 diabetes.
Elvinix receives rights to Zealand's preclinical peptide platform and associated data package, which is intended to stimulate pancreatic beta-cell regeneration while supporting metabolic control.
The deal transfers a non-core early-stage programme to a dedicated development company while preserving the potential for a disease-modifying approach to type 1 diabetes.
Field | Content |
Alert Type | Deal |
Companies | Zealand Pharma; Elvinix |
Deal Type | Exclusive licensing agreement |
Asset or Company | GLP-1/gastrin dual-agonist peptide platform |
Therapy Area(s) | Type 1 diabetes; metabolic disease; regenerative medicine |
Technology or Modality | Peptide therapeutics; GLP-1/gastrin dual agonism |
Development Stage | Preclinical |
Deal Value | Financial terms were not disclosed |
Geography | Global |
What Happened | Zealand Pharma licensed its GLP-1/gastrin dual-agonist peptide platform and associated preclinical package to Elvinix for development in type 1 diabetes. |
Why It Matters | The programme is intended to support pancreatic beta-cell regeneration, offering a potentially disease-modifying approach rather than solely replacing insulin or managing glucose. |
Supporting Context | Combining GLP-1 and gastrin activity has been investigated as a strategy for promoting beta-cell growth and improving pancreatic function. |
Strategic Rationale | Elvinix gains control of an early regenerative diabetes platform while Zealand can focus resources on its core pipeline and retain potential value from future development. |
Potential Impact | Successful development could introduce a regenerative therapeutic strategy aimed at restoring insulin-producing capacity in type 1 diabetes. |
Key Takeaway | Zealand has out-licensed a regenerative GLP-1/gastrin peptide platform to Elvinix for type 1 diabetes development. |
What to Watch | Preclinical validation, progression toward first-in-human studies and disclosure of development milestones under the licence. |
Primary Source | Zealand Pharma / Elvinix |
Relevant Date | 15 September 2026 |
Discover how nuaxia can support your next medical education initiative:
Find out more about our specialist services - Moore's Outcome Assessments, Educational Needs Assessments and Patient Impact Studies for the Medical Education sector
Contact us on: support@nuaxia.com
Comments